Search

Displaying results 3261 - 3270 of 10000 in total
  1. Drug

    ADL 10-0101

    go.drugbank.com/drugs/DB05443
    Experimental

    Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. … Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.

  2. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function

  3. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    numbness in the lower leg and walking disability associated with acquired lumbar spinal canal stenosis as an additional indication in 2001. … Ono and DSP also discontinued the development of limaprost alfadex for the additional indication of cervical spondylosis in 2008 due to the failure to demonstrate the anticipated efficacy in a Phase II

    Categories: Prostaglandins EProducts: OPALMON TABLETS 5 ug
  4. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    Sclerosis (MS). … It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.

  5. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).

  6. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

  7. Drug

    MM-093

    go.drugbank.com/drugs/DB05512
    Investigational

    MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults … Current studies are assessing MM-093’s potential to improve the treatment of autoimmune disease.

  8. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    It is currently classified under the Misuse of Drugs Act as a Class C substance [L2522]. … In addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516].

  9. Drug

    Isopropyl myristate

    go.drugbank.com/drugs/DB13966
    Approved

    [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].

  10. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

    Products: ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL